jRCT2071210038招募中不适用
Prevention of aggravation of moderate pneumonia caused by COVID - 19 using adrenomedullin - Investigator initiated phase 2a trial (AM-P2-COVID2)
未提供0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Hospitalized patients with moderate COVID-19 pneumonia and within 10 days after onset
排除标准
- •patients with severe COVID-19 pneumonia
- •patients with liver dysfunction (AST and/or ALT > 5 times of reference values)
- •patients with renal dysfunction (serum creatinine > 2.0 mg/dl)
- •patients with severe ECG abnormalities and/or cardiac diseases
- •patients with malignancy or history of malignancy
- •patients who are expected to transfer to other hospital within 72 hours
- •pregnant or lactating women
结局指标
主要结局
-
Period of oxygen administration (days)
次要结局
- The changes of cytokines
- the distribution of clinical status assessed on the 6-point ordinal scale(study day 10, 20 and 30)
- Adverse events
研究者
相似试验
已完成
1 期
Continuous intravenous adrenomedullin therapy for patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease)inflammatory bowel disease (ulcerative colitis and Crohn's disease)JPRN-UMIN000021421First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki10
尚未招募
不适用
Role of Midregional proadrenomedullin in detecting infection in newborn childreCTRI/2021/04/033251Sri Devaraj Urs Academy of Higher Education and Research
已完成
1 期
Multiple-dose administration study of adrenomedulliJPRN-jRCT2080224807niversity of MIyazaki12
招募中
Unknown
sing a blood test Adrenomedullin to predict disease severity andoutcome in patients with fever presenting to Emergency DepartmentCTRI/2023/07/054779Manipal Centre for Infectious Diseases (MACID)
进行中（未招募）
不适用
Adrenomedullin for CADASIL (AMCAD)jRCT205121011760